68Ga-DOTATATE与18F-FDG PET/CT定位异位ACTH分泌肿瘤的前瞻性头对头比较
在20例病理证实的EAS肿瘤中,68Ga-DOTATATE PET/CT正确识别15例(75.0%),18F-FDG PET/CT正确识别12例(60.0%),两者联合使18例(90%)患者肿瘤获得定位。结论认为两种显像互补,联合检测检出率高于任一单独显像。
要点
- 68Ga-DOTATATE PET/CT对EAS肿瘤的识别率为75.0%,高于18F-FDG PET/CT的60.0%。
- 68Ga-DOTATATE与18F-FDG PET/CT互补,联合可使90%患者肿瘤获得定位。
- 68Ga-DOTATATE在6例FDG阴性患者中检出病灶,FDG在3例DOTATATE阴性患者中检出病灶。
核心结论
- 68Ga-DOTATATE PET/CT与18F-FDG PET/CT在定位和鉴别EAS来源肿瘤方面具有互补性。
- 68Ga-DOTATATE PET/CT联合18F-FDG PET/CT的检出率高于任一单独显像。
研究设计与样本
- 23例患者接受手术切除或活检,并行SSTR2与Ki-67免疫组化染色,分别与68Ga-DOTATATE摄取和18F-FDG摄取进行关联分析。
主要发现
- 23例中20例观察到EAS肿瘤;20例病理证实的EAS肿瘤中,68Ga-DOTATATE PET/CT正确识别15例(75.0%),SUVmax范围1.4–20.7(6.7 ± 5.5)。
- 18F-FDG PET/CT正确识别12例(60.0%),SUVmax范围1.8–10.0(4.0 ± 2.1)。
- 68Ga-DOTATATE PET/CT在6例18F-FDG摄取阴性患者中揭示了EAS来源,18F-FDG PET/CT在3例68Ga-DOTATATE摄取阴性患者中揭示了EAS来源。
- 联合68Ga-DOTATATE PET/CT与18F-FDG PET/CT使18例(90%)患者EAS肿瘤获得识别。
关键数值与推荐
- EAS肿瘤识别率:68Ga-DOTATATE PET/CT为75.0%(15/20),18F-FDG PET/CT为60.0%(12/20),两者联合为90%(18/20)。
- 68Ga-DOTATATE PET/CT阳性病灶SUVmax为1.4–20.7(6.7 ± 5.5),18F-FDG PET/CT阳性病灶SUVmax为1.8–10.0(4.0 ± 2.1)。
临床怎么用
- 对疑似EAS患者,可考虑联合68Ga-DOTATATE PET/CT与18F-FDG PET/CT以提高肿瘤定位检出率。
- 任一显像阴性时不应单独排除EAS肿瘤,另一显像可能揭示病灶来源。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Localizing the source of ectopic adrenocorticotropic hormone secretion (EAS) is challenging. This study compared the diagnostic value of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in tumors with EAS. METHODS: Thirty-six patients with a suspicion of EAS were enrolled to undergo both 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT within 4 weeks for comparison. Twenty-three underwent surgical resection or biopsy. Immunohistochemical staining for SSTR2 and Ki-67 was performed to correlate with 68Ga-DOTATATE uptake and 18F-FDG uptake, respectively. RESULTS: EAS tumors were observed in 20/23 patients. Among the 20 patients with histologically proven EAS tumors, 68Ga-DOTATATE PET/CT correctly identified the tumor in 15 (75.0%), with an SUVmax ranging from 1.4 to 20.7 (6.7 ± 5.5). 18F-FDG PET/CT correctly identified the tumor in 12 (60.0%) patients, with an SUVmax ranging from 1.8 to 10.0 (4.0 ± 2.1). Moreover, 68Ga-DOTATATE PET/CT unmasked the sources of EAS in 6 patients with negative 18F-FDG uptake, and 18F-FDG PET/CT unmasked the sources in 3 patients with negative 68Ga-DOTATATE uptake, resulting in EAS tumors being identified in 18 (90%) patients by combining 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT. CONCLUSIONS: 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT are complementary in localizing and discriminating the source of EAS. 68Ga-DOTATATE PET/CT combined with 18F-FDG PET/CT had higher detection rate than each alone. TRIAL REGISTRATION: 68Ga-DOTATATE PET/CT in Neuroendocrine Tumors (NCT04041882) URL OF REGISTRY: https://clinicaltrials.gov/ct2/show/NCT04041882.
引用
- Liu Q, Zang J, Yang Y, et al. Head-to-head comparison of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in localizing tumors with ectopic adrenocorticotropic hormone secretion: a prospective study. Eur J Nucl Med Mol Imaging. 2021. PMID: 34146130. doi:10.1007/s00259-021-05370-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。